Jun 21, 2022
OnDosis säkrar 75 miljoner kronor med AstraZeneca och Aeternum Capital som ankarinvesterare
OnDosis, ett svenskt life science-bolag som utvecklar en ny device-teknologi för precisionsdosering av läkemedel, meddelar idag att Bolaget har säkerställt en investering på totalt 75 miljoner kronor. Bland investerarna märks OnDosis-grundarna AstraZeneca och Martin Olovsson, samt större ägare som Aeternum Capital, DIG Investment och Rydgruppen.
Read moreJun 21, 2022
OnDosis completes a private placement of SEK 75 million supported by AstraZeneca and Aeternum Capital
OnDosis, a Swedish Life science company developing a new drug/device technology platform, announced today that the Company has completed a private placement of SEK 75 million. Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen.
Read moreMay 31, 2022
Notice of annual general meeting 2022
The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby given notice of Annual General Meeting on Tuesday 28 June 2022 at 10.00 (CEST) at the Company's premises at Pepparedsleden 1 in Mölndal. Admission and registration will take place at the AstraZeneca KC entrance at 09.45 (CEST).
Read moreMay 31, 2022
Kallelse till årsstämma i Ondosis AB
Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till årsstämma tisdagen den 28 juni 2022 kl. 10.00 i Bolagets lokaler på AstraZeneca Bio VentureHub, Pepparedsleden 1 i Mölndal. Insläpp och registrering sker vid AstraZeneca KC entrén kl. 09:45.
Read moreMay 31, 2022
2021 årsredovisning
Styrelsen och den verkställande direktören för OnDosis AB (publ) med org.nr 559113-1825 och säte i Göteborg, får härmed avge årsredovisning för räkenskapsåret 2021-01-01 - 2021-12-31.
Read moreMay 31, 2022
2021 Annual report
The Board of Directors and the CEO of OnDosis AB (publ), and based in Gothenburg, with corporate identity number 559113-1825 hereby present the company’s Annual Report for the financial year 2021-01-01 to 2021-12-31.
Read moreJan 11, 2022
Kallelse till extra bolagsstämma i ondosis ab
Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till extra bolagsstämma tisdagen den 25 januari 2022 kl. 15.00 i Bolagets lokaler på Pepparedsleden 1 i Mölndal.
Read moreJan 11, 2022
Notice of extra general meeting in ondosis ab
The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby invited to the extra general meeting on Tuesday 25 January 2022 at 15.00 CET at the Company's premises at Pepparedsleden 1 in Mölndal.
Read moreMay 25, 2021
New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Read moreMay 25, 2021
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
Read moreFeb 10, 2021
New business partner and international recognition for OnDosis
OnDosis wants to revolutionize the way we take our medicines. The idea is that every single patient, in the easiest possible way, shall get precisely the right amount of medicine and thus lead a better life. Now the company begins a cooperation with Opatus, whose digital tool objectively scales symptoms of ADHD patients. In addition, OnDosis recently received a double recognition at the largest conference concerning ADHD and related diseases in USA—and there is a growing interest in the company in other areas too.
Read moreSep 11, 2020
OnDosis announces commitment of 30 MSEK raise from existing owners and DIG Investment
Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.
Read moreSep 10, 2020
Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.
Read moreNov 25, 2019
OnDosis selected to pitch at European Angel Investment Summit
This week, OnDosis is one of 40 startups who will get to pitch in front of investors from all over the world at European Angel Investment Summit in Brussels 25–26 November. In addition, we're participating at The 29th MedTech Investing Europe Conference in London 26–27 November. Read more: http://europeanangelsummit.com/startups/ http://www.medtechinvesting.com/
Nov 15, 2019
Major article on the opportunities with On Dosis in IPI Magazine
Pharmaceutical innovation is accelerating fast, but the way of dosing oral medicines to patients has very much stayed the same. This article in IPI magazine, “Beyond the Pill Personalisation by Integrating Oral Medication and Digitalisation”, highlights the opportunities with OnDosis.
Read moreAug 15, 2019
OnDosis awarded Horizon 20/20 funding and attending key meetings to broaden partnerships
During the first half of 2019 OnDosis was awarded a European Union’s Horizon 2020 Research and Innovation Programme SME (Small and Medium sized Enterprises) instrument for phase 1. This will help OnDosis progress the work in developing its product for ADHD. Supporting its connectivity interface OnDosis has also been contracted by a EUREKA cluster 5G project.
Read moreApr 23, 2019
Shaping the journey of a new life science company?
After two successful years since being founded, OnDosis is accelerating. We are now looking for a Co-Pilot to the CEO, a position which will be critical in order to drive the company towards our ambition. We are looking for an energetic doer. A person that is making things happen, connecting dots and building relationships. This individual will grow with OnDosis and be part of a small but dynamic leadership team. Is it you?
Read moreMar 22, 2019
OnDosis has been chosen as one of the companies selected to the Swedish IVA 100 list
The IVA (Royal Swedish Academy of Engineering Sciences) is an independent academy whose mission is “...to promote the engineering and economic sciences and the advancement of business and industry for the benefit of society”. IVA’s list brings together research that can form the basis of innovation in the form of new companies, new products and services, business development or other form of benefit.
Read moreDec 04, 2018
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.
Read moreOct 18, 2018
Introducing OnDosis, a new life science company
Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.
Read more
Jun 30, 2022
Ondosis säkrar 75 mkr inytt kapital – utvecklarsamarbetet medTiefenbacher
Life science-företaget Ondosis har säkerställt en investering på totalt 75 miljoner kronor från bland andra Ondosis-grundarna Astrazeneca och bolagets vd Martin Olovsson. Bland investerarna finns även Aeternum Capital, DIG Investment och Rydgruppen,
Read more
Jun 22, 2022
OnDosis completes a private placement of 75 million SEK
Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen.
Read more
Press material
Download images and logotype approved for press use here.
